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Fractionated stereotactic radiation therapy
improves cranial neuropathies in patients with
skull base meningiomas: a retrospective cohort
study
Xinglei Shen1,7*, David W Andrews2, Robert C Sergott3, James J Evans2, Walter J Curran4, Mitchell Machtay5,
Ruben Fragoso6, Harriet Eldredge1,8, Colin E Champ1,8, Matthew Witek1,8, Mark V Mishra1,8, Adam P Dicker1,8
and Maria Werner-Wasik1,8
Abstract
Background: Skull base meningiomas commonly present with cranial neuropathies. Fractionated stereotactic
radiation therapy (FSRT) has been used to treat these tumors with excellent local control, but rates of improvement
in cranial neuropathies have not been well defined. We review the experience at Thomas Jefferson University using
FSRT in the management of these patients with a focus on symptom outcomes.
Methods: We identified 225 cases of skull base meningiomas treated with FSRT at Thomas Jefferson University
from 1994 through 2009. The target volume was the enhancing tumor, treated to a standard prescription dose of
54 Gy. Symptoms at the time of RT were classified based on the cranial nerve affected. Logistic regression was
performed to determine predictors of symptom improvement after FSRT.
Results: The median follow-up time was 4.4 years. In 92% of cases, patients were symptomatic at the time of RT;
the most common were impaired visual field/acuity (58%) or extraocular movements (34%). After FSRT, durable
improvement of at least one symptom occurred in 57% of cases, including 40% of visual acuity/visual field deficits,
and 40% of diplopia/ptosis deficits. Of all symptomatic patients, 27% experienced improvement of at least one
symptom within 2 months of the end of RT.
Conclusions: FSRT is very effective in achieving improvement of cranial neuropathies from skull base meningiomas,
particularly visual symptoms. Over half of treated patients experience a durable improvement of at least one
symptom, frequently within 2 months from the end of RT.
Keywords: Fractionated stereotactic radiation therapy, Meningioma, Symptom, Outcome, Skull base
Background
Meningiomas are benign tumors which account for
approximately 25% of primary intracranial tumors [1]. A
significant proportion arises in the skull base region,
where they are often difficult to access surgically and fre-
quently cause cranial neuropathies. Definitive treatment
recommendations for these tumors include radiation
therapy (RT) and surgery (with post-operative RT after
subtotal resection) [2,3]. Following complete or subtotal
resection without RT, 5 year progression free survival
ranges from 81-95% [2-4].
RT can provide excellent local control in the definitive
and post-operative settings. Single institution series of
fractionated RT using either 3-D conformal RT [5,6], in-
tensity modulated radiation therapy (IMRT) [7], or fractio-
nated stereotactic radiation therapy (FSRT) [8-10] have
reported local control rates of 90-100%. Stereotactic radio-
surgery (SRS) with Gamma Knife or linear accelerator
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(LINAC) based SRS have also resulted in excellent local
control [11-13].
Although local control data have been extensively
described, most series fail to evaluate symptomatic
outcomes for these patients. An overview of published
literature indicated that 14-44% of patients have clinical
neurological improvement after FSRT, and up to 95%
have stabilization of neurologic symptoms [14]. How-
ever, a paucity of literature exists with regards to details
of symptom outcomes, such as timing of symptom im-
provement, durability of symptom improvement, and
prognostic factors.
At our institution, we have treated skull base menin-
giomas both definitively and post-operatively with FSRT
since 1994. Our institutional philosophy has been to pre-
ferentially treat skull base meningiomas with FSRT
instead of SRS based on the theoretical radiobiological
advantage of fractionation to achieve greater sparing and
recovery of sensitive normal structures such as the optic
apparatus. We have observed an unexpected rate of du-
rable symptomatic improvement during and soon after
FSRT treatment. This report will review our experience
of treating patients with skull base meningiomas with
FSRT, focusing our analysis and discussion on symptom
outcomes.
Methods
Patient selection
We reviewed all patients with skull base meningiomas
treated with FSRT from 1/1/1994 to 3/1/2009. Skull base
meningiomas were defined as any clinically or pathologi-
cally diagnosed meningioma which involved the cavernous
sinus, sphenoid, clinoid, sella, suprasellar region, cerebel-
lopontine angle, petroclival region, foramen magnum,
clivus, or designated as skull base, not otherwise specified
(which tended to be large tumors encompassing multiple
regions). For analysis of local control, we classified patients
into four treatment categories: RT alone, adjuvant RT (after
subtotal or near total resection), RT for progression/recur-
rence after surgery, or re-irradiation (with or without prior
surgery).
Radiation delivery
All patients were treated on a dedicated stereotactic linear
accelerator (Varian SR600 or Novalis TX). Gross tumor
volume (GTV) was equivalent to clinical target volume
(CTV) and planning target volume (PTV), and was
defined as the contrast enhancing tumor only. Our stan-
dard prescription dose was 54 Gy (range 10 – 60 Gy, me-
dian 52.2 Gy) in 1.8 or 2.0 Gy/fraction. Dose was reduced
in 56% of cases when the optic chiasm dose exceeded
56–57 Gy, or in re-irradiation cases. Prior to 2004, treat-
ment planning was performed on the Radionics XKnife
(Radionics, Inc., Burlington, MA) treatment planning
system, with multi-isocenter plans (median 79% isodose
line) using spherical collimators and Gill-Thomas-Cosman
frames for patient immobilization. After 2004, patients
were planned with BrainLab (BrainLAB AG, Feldkirchen,
Germany) treatment planning system with single isocenter
conformal plans using 5 dynamic arcs (median 90% isodose
line), and thermoplastic mask for patient immobilization
with position verification using ExacTrac kV daily imaging.
Static stereotactic intensity modulated radiation therapy
(IMRT) was introduced in 2004, and was generally used
for large tumors with eccentric shapes or those close to
critical structures.
Follow-up
Patients followed up with a radiation oncologist at
6 weeks after completion of RT. Subsequent follow-up
visits with either a radiation oncologist or neurosurgeon
occurred at 3 months, 6 months, and 1 year, and then
yearly and bi-annually up to 10 years, and then per
patient preference afterwards. Length of follow-up was
defined as time from the start of RT to the last follow-
up with radiation oncology or neurosurgery. Time to
progression was defined as the time from start of RT to
the date of first radiographic evidence of progression.
Symptoms and toxicity
Symptoms were classified into major categories based on
the cranial nerves (CN) involved: visual field/visual acuity
(CN2), extra-ocular movements/ptosis (CN3, 4, 6), facial
sensation (CN5), facial strength (CN7), hearing/balance/
tinnitus (CN8), swallowing/tongue weakness (CN9-12),
and other (including long tract signs and symptoms due
to mass effect such as headache and proptosis). We
included all symptoms at time of RT, including those
which first appeared in the post-operatively. Duration of
symptoms prior to RT was calculated from date of initial
symptom presentation to start of RT. Durability of symp-
tom improvement or worsening was defined as a conti-
nued subjective change or physical exam difference at the
time of last followup compared to pre-RT baseline. Time
to improvement and time to worsening were calculated
from the start of radiotherapy to the date of change.
Adverse events were defined as development of a new cra-
nial neuropathy such as radiation induced optic neuritis
(RION), trigeminal neuropathy, or other symptoms not
associated with tumor progression. Radiographic findings
of radiation necrosis were included as adverse events,
regardless of symptoms.
Data analysis
Statistical analysis was performed using SAS v9.2 (SAS
Institute Inc, Cary, NC). Freedom from progression was
estimated using Kaplan-Meier method, with differences
between treatment groups calculated using the log-rank
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test compared to the RT alone group. Events were
censored at last follow-up. We used univariate and back-
wards stepwise multivariate Cox proportional hazards
models to estimate the hazard ratios of factors associated
with tumor progression. The initial multivariate model
included age, sex, prior RT, midline or bilateral location,
presence of symptoms at presentation, use of IMRT, use
of BrainLab planning system, prior surgery, treatment
group, GTV size, fraction size (≥2 Gy vs. < 2 Gy), total
dose, time from diagnosis to RT, and pathologic grade, if
known. A two sided α < 0.05 was considered significant.
Univariate and backwards stepwise logistic regression
model was used to determine factors associated with any
symptom improvement. Covariates in the initial multi-
variate model included duration of symptoms prior to
RT, age, gender, GTV size, fraction size, total dose, prior
surgery, re-irradiation, midline or bilateral location, use
of IMRT, and use of BrainLab planning system. We used
logistic regression to determine the odds ratio (OR) of
worsening of symptoms events in cases with progression
compared to those without progression. A two sided
α <0.05 was considered significant.
Results
Patient characteristics
This retrospective study was conducted after approval
by the institutional review board at Thomas Jefferson
University. We identified 278 patients treated with
FSRT for skull base meningiomas from 1/1/1994
through 3/1/2009. Follow-up data were available on
217 patients (78.1%). The median follow-up time was
4.4 years. Seven patients were treated with a second
course of FSRT, totaling 224 courses of FSRT included in
the analysis. We considered each treatment course as a
separate case for the purposes of analyses (Table 1). The
majority of patients were female (74%), and the median
age at the time of radiation therapy was 60.7 years old.
Ninety-two percent of cases were symptomatic at the
time of FSRT; the remaining cases were treated for
asymptomatic progression. The most common area of
involvement was the cavernous sinus (30%) or sphenoid/
clinoid region (29%). These data represent approxima-
tions as tumors often encompassed multiple regions.
Treatment consisted of RT alone in 51% of cases, adju-
vant RT in 18%, RT for progression/recurrence after prior
surgery in 26%, and re-irradiation in 5% of cases.
Local control
Twenty-one patients progressed after FSRT, representing
a 90.6% cumulative freedom from local failure. Local
control at 5 years was 96.1% in the RT alone group,
96.8% (p=0.75) in the post-operative group, 77.3%
(p=0.04) in the progression/recurrence after surgery
group, and 44.4% (p < 0.01) in the progression after
radiation group (Figure 1). In addition to treatment group,
recurrence after prior RT (Hazard ratio (HR) 8.4, p<0.01),
midline/bilateral tumor location (HR 2.9, p=0.02), any
prior surgery (HR 2.51, p=0.05), treatment volume per
each cm [3] larger (HR 1.032, p=0.03) and use of IMRT
Table 1 Patient characteristics
Variable n Percent
Median Age (years) 60.7 (range 21–92)
Median Tumor Volume (cc) 8.7 (range 0.67 – 62.2)
Gender:
Male 58 25.9%
Female 166 74.1%
Location:
Cavernous sinus 66 29.5%
Parasellar 9 4.0%
Sphenoid/clinoid 65 29.0%
CPA 32 14.3%
Clivus 7 3.1%
Sellar/suprasellar 16 7.1%
Planum 15 6.7%
Craniocervical 13 5.8%
Other 1 0.4%
Laterality
Left 95 42.4%
Right 84 37.5%
Midline/Bilateral 44 19.6%
Unknown 1 0.4%
Symptoms at time of Radiation
Symptomatic 205 91.5%
Asymptomatic 19 8.6%
Intensity Modulate Radiation Therapy
Yes 41 18.3%
No 183 81.7%
Neurofibramatosis-2 3 1.4%
Treatment Group*:
Radiation only 115 51.3%
Adjuvant radiation 40 17.9%
Progression after surgery 58 25.9%
Re-irradiation 11 4.9%
Pathology
No pathologic diagnosis 112 50.0%
WHO grade I 108 48.2%
WHO grade II 4 1.8%
Dose
> 52.5 Gy 125 55.8%
<= 52.2 Gy 99 44.2%
* Per treatment course. Seven patients in the radiation only, adjuvant radiation
or progression after surgery groups are also present in the re-irradiation group
because they underwent a second course of fractionated stereotactic radiation
therapy.
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(HR 2.73, p=0.04), were significantly correlated with
increased rate of local failure on univariate analysis. Total
dose, use of BrainLab planning system, being symptomatic
at presentation and fraction size were not correlated with
local failure. On multivariate analysis, midline/bilateral lo-
cation (HR 2.97, p=0.02), atypical histology (HR 8.70,
p=0.01) and treatment group were associated with local
failure. Compared to RT alone, adjuvant RT (HR 0.82,
p=0.79) and RT for recurrence after surgery (HR 1.78,
p=0.32) were not significantly different; however, re-
irradiation (HR 11.02, p<0.01) was a significant predictor
of subsequent local failure.
Symptom presentation
Patients were symptomatic at the start of treatment in
92% of cases. The most common presenting symptoms
were decreased visual acuity/visual field deficits (57.6%)
and diplopia/ptosis (33.5%) (Table 2). In our cohort, the
frequency of patients who received surgery prior to RT
differed in each symptom category. Approximately 40% of
cases presenting with diplopia or ptosis had surgery prior
to RT, while 90% of those presenting with facial weakness
or CN9-12 deficits had surgery prior to RT. Symptoms
were first noted in the post-operative setting in several
cases, including facial weakness (50%), CN9-12 deficits
(37.5%) and decreased facial sensation (18%). The median
duration of symptoms prior to radiation was generally
around 1 year (Table 2), and was longer in cases with prior
surgery (data not shown).
Symptom outcomes
Symptom outcomes varied according to initial symptoms
(Figure 2). The outcomes of 10-30% of symptoms after
FSRT were not documented, particularly for those related
to hearing and balance. Among cases without tumor
progression, 30-40% had durable improvement, 30-40%
had stable symptoms, and less than 10% had symptom de-
terioration after FSRT (Figure 2). The most common
presenting symptom, visual acuity and visual field deficits,
was durably improved in 37% of cases, maintained in 35%,
and deteriorated after tumor progression or treatment
related adverse event in 14%. Additionally several patients
developed new symptoms attributable to co-morbid condi-
tions, such as worsening vision in a patient with HSV kera-
titis or new deficits following a stroke. Durable symptom
improvement of at least one symptom occurred in 57% of
cases.
Symptom improvement typically occurred within
6 months of the start of FSRT (Table 3), and often
earlier. By the last day of FSRT course, 17% of cases had
experienced improvement in at least one symptom, and
by 2 months after FSRT, 27% of cases had improvement
in at least one symptom. Of cases with symptom im-
provement, 33% first occurred by the end of FSRT and
54% within 2 months after FSRT. In contrast, symptom
deterioration was observed many months later (median
18.7 months). In the absence of tumor progression,
89% – 100% of symptom improvements were durable
at the time of last follow-up. For an illustrative
example of early symptom improvement (Table 4 and
Figure 3).
Symptoms and progression
Symptom worsening occurred more often in cases where
tumors progressed (68% vs. 13%, p < 0.01). Patients with
tumor progression had a 12 fold increased odds of symp-
toms worsening (OR 12.29 95% CI 4.6 – 32.6, p < 0.01).
The most common presenting symptom, visual field/vis-
ual acuity deficit, worsened in 12 of 17 (70.6%) patients
who ultimately experienced progression. Worsening of
symptoms commonly preceded objective radiographic
finding of tumor progression (data not shown).
Predictors of symptom improvement
On univariate analysis, prior surgery (OR 0.44, 95% CI
0.25-0.78), midline/bilateral location of tumor (OR 0.44,
95% CI 0.22-0.90), and re-irradiation (OR 0.18, 95% CI
0.38-0.88) were negative predictors of symptomatic im-
provement after FSRT. Of note, GTV size, fraction size,
total dose, use of IMRT, use of BrainLab planning system,
and duration of symptoms prior to FSRT were not asso-
ciated with symptom improvement. On multivariate
analysis, any prior surgery (OR 0.47, 95% CI 0.25-0.86),
and age (per 10 years older) (OR 0.78, 95% CI 0.62-0.98)
were negative predictors of symptom improvement, while
re-irradiation (OR 0.40, 95% CI 0.11 – 1.40), midline/bila-
teral location was no longer significant (OR 0.53, 95% CI
0.25-1.11) (Table 5).
Adverse outcomes
We noted 32 adverse events in 28 patients (12.5% cumu-
lative incidence). The most common adverse events were
Figure 1 Kaplan meier local control by treatment group. Seven
patients in the re-irradiation arm are also counted in one other arm
because of recurrence. Compared to radiation therapy (RT) alone,
adjuvant RT was not different (p=0.98), but recurrence after prior
surgery (p = 0.02) and re-irradiation (with or without prior surgery)
groups (p<0.01) were different.
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radiation induced optic neuritis (n = 5, 2.2%), radiation
necrosis (n = 5, 2.2%) and facila numbness or pain (n = 5,
2.2%). Additional adverse events included three cases of
hypothyroidism, two cases each of diplopia, significant
cognitive decline, and occipital neuralgia, and one case
each of dysphagia, facial myoclonus, glossopharyngeal
neuralgia, seizures,, diabetes insipitus, and vertigo.
Discussion
We present the results of our institutional experience with
FSRT for the treatment of skull base meningiomas. Our
local control outcomes are consistent with other reports of
5 year progression free survival rates of 87–95.7% after
treatment with either SRS [11-13,15] or FSRT [8-11]. Since
many of these patients are symptomatic at presentation
(92% in our cohort) we feel that symptom outcome is a
crucial end-point in addition to local control and overall
survival, which tend to be universally excellent in published
reports. This report adds to the existing literature on by
providing a detailed analysis dissected by symptom domain
in a large retrospective cohort. These patients were closely
followed during RT, allowing detection of a high rate of
symptom improvement early in the treatment course.
We found that in addition to providing excellent local
control, FSRT resulted in durable symptom improve-
ment of one or more symptoms in 57% of cases. For
patients with reduced vision, FSRT durably improved or
maintained vision in at least 71% of cases, demonstrating
the utility of FSRT in function preservation. While less
detailed, other series in the literature have also reported
between a 5-46% rate of improvement in symptoms
following radiation therapy with either SRS or FSRT
[8,9,15,16]. We have not attempted to compare these
results with those reported from SRS or surgical series
because =of multiple potential confounding factors such
as case mix, recall bias and reporting bias.
We found a negative association between prior sur-
gery, re-irradiation and increasing age with the likeli-
hood of symptom improvement after FSRT. These
finding suggest FSRT after prior definitive treatment is
less likely to result in symptomatic improvements,
particularly in older patients. Midline or bilateral lo-
cation was a negative prognostic factor for symptom
Table 2 Distribution of presenting symptoms at the time of radiation therapy
Domain Number of cases Percent of all cases* Median duration (months)** Prior surgery New symptom post-op***
Visual Acuity/Visual Field 129 57.6% 12.8 51.9% 0.8%
Any Diplopia/Ptosis 75 33.5% 9.9 41.3% 2.7%
Cranial Nerve III 37 16.5%
Cranial Nerve IV 8 3.6%
Cranial Nerve VI 39 17.4%
Unspecified 20 8.9%
Facial Sensation 50 22.3% 9.9 50.0% 18.0%
Facial Weakness 12 5.4% 8.4 91.7% 50.0%
Hearing 34 15.2% 13.6 50.0% 17.6%
Balance 32 14.3% 12.9 43.8% 6.3%
Tinnitus 7 3.1% 26.4 28.6% 0
Cranial Nerve IX -XII 8 3.6% 14.7 100% 37.5%
Other 61 27.2% 9.7 45.9% 3.3%
Asymptomatic 19 8.5% – 47.4% –
* Do not add up to 100% because some patient presented with multiple symptoms.
**Duration of symptom prior to radiation therapy.
***Among cases with the specific deficit at radiation, percent where the symptom only appeared in the post-operative setting.
Figure 2 Symptom outcome after FSRT in cases without
progression and with progression. Symptom outcomes
(improved, stable, comorbidity, stable) refer to the final status of the
symptom at last followup. Comorbidity refers to symptom
worsening due to a co-morbid disease process and unrelated to
tumor progression or treatment. The number of cases is greater
than number who presented with each symptom because some
patients developed new deficits due to worsening of symptoms
from either tumor progression, treatment toxicity or co-morbid
disease.
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improvement, a finding which has not been reported
previously. Midline and bilateral tumors were larger,
received less radiation dose, and underwent resection
prior to radiation more often. It is unclear whether this
finding is the result of an intrinsic property of tumors of
this region or a spurious finding as a result of multiple
comparisons, and should be investigated in future stud-
ies. Of interest, despite evolving technology, the use of
the BrainLab treatment planning system, a surrogate for
patients treated prior to 2004 versus those treated after
2004, predict for either local control or symptom
improvement.
When patient symptoms improved, they did so by the
end of FSRT in one third of patients, and within two
months of the end of FSRT in over half of patients. This
observation of the early symptom improvement raises
questions regarding the underlying mechanism. Such
improvement was also reported in the literature to occur
at 6 weeks after completion of IMRT [17] and FSRT
[18]. This time frame typically precedes radiographic
shrinkage and likely occurs before the full tumoricidal
effect of radiation. A placebo effect is unlikely to account
for this symptoms relief, as patients were noted to have
objective responses on cranial nerve examinations dur-
ing weekly treatment visits. Although speculative, one
possible explanation for restoration of cranial nerve
function after radiation is re-distribution of vascular flow
from tumor to the affected cranial nerve(s).
Conversely, while radiographic improvement does not
necessarily correlate with symptomatic improvement,
there was a strong relationship between radiographic
tumor progression and symptom worsening. The mecha-
nism of symptom worsening may differ from that of im-
provement. Indeed, the clinical finding of a new symptom
may be an early indicator of radiographic progression.
Treatment was generally very well tolerated and adverse
events were infrequent in our series, though estimates
were conservative and included all possible treatment
related events. Our reported rates of RION (2.2%) and
radiation necrosis (2.2%) were low and may still over-
estimate the actual adverse event rates, supporting FSRT
as a safe treatment option.
Limitations to our study include limited documentation
of symptom severity and relatively short median follow-up
Table 3 Timing and durability of symptom improvement
Domain Median time to improve
(mo.)
Range
(mo.)
Durability of
improve*
Median time to worsening (mo.)
(range)
Range
(mo.)
Visual Acuity/Field 3.2 0.1 - 30.1 92.7% 25.0 0.2 - 98.2
Diplopia/Ptosis 4.6 0.6 - 128.7 88.2% 47.0 0.5 - 85.9
Facial Sensation 4.8 0.6 - 58.6 93.3% 17.3 2.5 - 102.7
Facial Weakness 16.8 1.1 - 42.8 100% 33.3 1.9 - 64.9
Hearing – 2.1 - 2.7 – 5.1 2.5 - 82.8
Balance 2.4 2.8 - 2.8 100% 11.1 2.8 - 114.0
Tinnitus 2.8 100% 3.5 2.4 - 4.6
Cranial Nerve IX-
XII
4.9 4.2 - 5.6 100% 24.6 6.4 - 31.5
Other 2.4 0.5 - 5.6 91.7% 9.5 2.4 - 20.3
* Durability defined as percent of symptoms which after initial improvement remained improved over pre-radiation baseline at the time of last follow-up.
Table 4 Example of very early visual acuity improvement during fractionated stereotactic radiation therapy course
Date Visit reason Time from start of RT (months) Visual acuity left eye Humphrey visual field (MSD/PD*) left eye
2/21/2006 Initial Consult – 20/200+ −26.52/6.96
4/7/2006 On treatment (27 Gy) 0.6 20/100
4/12/2006 On treatment (32.4 Gy) 0.8 20/50
6/1/2006 Follow-up 2.4 20/30 −7.51/7.25
2/8/2007 Follow-up 11 20/25 −5.21/4.81
2/14/2008 Follow-up 23 20/25
11/18/2009 Follow-up 44 20/25 −5.76/7.60
*Mean standard deviation/Percent deviation.
Patient M.R. initially presented with left visual field deficits and decreased visual acuity in 1996 and underwent a subtotal resection of a left cavernous sinus
meningioma with improvement. He had symptomatic worsening in 2005, and a radiographic evidence of progression in January 2006. He received FSRT from
3/20/2006 to 4/27/2006 reporting subjective improvement in vision in the third week of fractionated stereotactic radiation therapy, confirmed objectively on
physical examination by Snellen chart using a near card. Objective improvement was also confirmed on Humphrey visual field testing. His vision remained
excellent through last follow-up.
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time. Although we recorded symptom severity, these were
often recorded as subjective rather than objective mea-
sures. Some of patients did have objective measurement
of symptom outcomes, such as with visual field testing,
and these have typically correlated well with objective
findings. We have chosen to not report the objective fin-
dings in this report as they represent only a subset of the
overall cohort and may not be representative of overall
outcomes. Additionally, given the difficulty in comparing
severity between symptom domains, we did not use this
measure in analysis.
The median follow-up time (4.4 years) is short given
the range of patients who were treated from 1994
through 2009. Factors for this finding include losses to
follow-up from patients who live far from our facility
and to storage from paper records. Additionally, we
strictly defined follow-up as the last evaluation by a
radiation oncologist or a neurosurgeon, rather than the
last evidence of patient being alive, in order to capture
symptom outcomes. A quarter of our patients had follow-
up greater than 5.8 years, permitting a limited evaluation
of long term toxicity and symptom outcomes.
Conclusions
Fractionated stereotactic radiation therapy offers a safe
and effective treatment option for patients with skull
base meningiomas. Over half of patients experience du-
rable improvement in one or more symptoms, often
within a few months following the start of radiation
therapy. Our results support FSRT as a safe and effective
treatment for patients with base of skull meningiomas.
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Figure 3 Example of plan from case of very early visual acuity improvement during FSRT course. Patient was treated to 52.2 Gy at 1.8
Gy/fraction to the 95% iso-dose line using an eight field stereotactic fractionated intensity modulated radiation therapy plan.
Table 5 Multivariate predictors of symptom improvement
Predictor (Multivariate) Odds ratio 95% CI p-value
Age (per 10 years older) 0.78 0.62 – 0.98 0.03
Prior Surgery* 0.47 0.25 – 0.86 0.01
Re-irradiation 0.40 0.11 – 1.40 0.15
Midline/Bilateral location 0.53 0.25 – 1.11 0.09
Symptom improvement defined as improvement of at least one symptom
compared to prior to radiation therapy. Multivariate model based on
backwards stepwise logistic regression.
*Patients who either received adjuvant radiation or salvage radiation after
prior surgery alone.
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